{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:11:11Z","timestamp":1764936671231},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt359","type":"journal-article","created":{"date-parts":[[2013,9,8]],"date-time":"2013-09-08T00:50:16Z","timestamp":1378601416000},"page":"2985-2989","source":"Crossref","is-referenced-by-count":23,"title":["Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial"],"prefix":"10.1016","volume":"24","author":[{"given":"E.","family":"de Azambuja","sequence":"first","affiliation":[]},{"given":"D.","family":"Zardavas","sequence":"additional","affiliation":[]},{"given":"M.","family":"Lemort","sequence":"additional","affiliation":[]},{"given":"J.","family":"Rossari","sequence":"additional","affiliation":[]},{"given":"C.","family":"Moulin","sequence":"additional","affiliation":[]},{"given":"A.","family":"Buttice","sequence":"additional","affiliation":[]},{"given":"V.","family":"D'Hondt","sequence":"additional","affiliation":[]},{"given":"F.","family":"Lebrun","sequence":"additional","affiliation":[]},{"given":"Y.","family":"Lalami","sequence":"additional","affiliation":[]},{"given":"F.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"C.","family":"Sotiriou","sequence":"additional","affiliation":[]},{"given":"T.","family":"Gil","sequence":"additional","affiliation":[]},{"given":"D.","family":"Devriendt","sequence":"additional","affiliation":[]},{"given":"M.","family":"Paesmans","sequence":"additional","affiliation":[]},{"given":"M.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[]},{"given":"A.","family":"Awada","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"4785","key":"10.1093\/annonc\/mdt359_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"7\u20139","key":"10.1093\/annonc\/mdt359_bb0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1387\/ijdb.113396se","article-title":"The epidermal growth factor receptor\/Erb-B\/HER family in normal and malignant breast biology","volume":"55","author":"Eccles","year":"2011","journal-title":"Int J Dev Biol"},{"issue":"1","key":"10.1093\/annonc\/mdt359_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives","volume":"9","author":"Arteaga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdt359_bb0025","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U","article-title":"Brain metastases. Histology, multiplicity, surgery, and survival","volume":"78","author":"Nussbaum","year":"1996","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdt359_bb0030","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt359_bb0035","doi-asserted-by":"crossref","first-page":"36s","DOI":"10.1200\/jco.2007.25.18_suppl.1018","article-title":"Trastuzumab treatment and the risk of central nervous system (CNS) metastases","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdt359_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","article-title":"Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood\u2013brain barrier","volume":"18","author":"Stemmler","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdt359_bb0045","series-title":"Brain Metastasis: a Unique Microenvironment and a Sanctuary from Chemotherapy","first-page":"91","author":"Steeg","year":"2010"},{"issue":"3","key":"10.1093\/annonc\/mdt359_bb0050","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-011-0601-8","article-title":"Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer","volume":"29","author":"Taskar","year":"2012","journal-title":"Pharm Res"},{"issue":"2","key":"10.1093\/annonc\/mdt359_bb0055","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1535-7163.MCT-06-0423","article-title":"Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling","volume":"6","author":"Nahta","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1093\/annonc\/mdt359_bb0060","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2007.12.3588","article-title":"Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdt359_bb0065","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"18S","key":"10.1093\/annonc\/mdt359_bb0070","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/jco.2007.25.18_suppl.1012","article-title":"EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)","volume":"25","author":"Lin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdt359_bb0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/13543784.2011.580736","article-title":"Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?","volume":"20","author":"Addeo","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"17","key":"10.1093\/annonc\/mdt359_bb0080","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdt359_bb0085","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/cncr.22127","article-title":"Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma","volume":"107","author":"Rivera","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdt359_bb0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdq434","article-title":"Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine","volume":"22","author":"Metro","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt359_bb0095","article-title":"LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR) 2011","volume":"9","author":"Bachelot","year":"2011","journal-title":"ASCO Annual Meeting J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt359_bb0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/COC.0b013e318194f744","article-title":"Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature","volume":"33","author":"Platta","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdt359_bb0105","article-title":"CEREBEL (EGF111438): An open label randomized Phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC)","author":"Pivot","year":"2012","journal-title":"ESMO"},{"issue":"2","key":"10.1093\/annonc\/mdt359_bb0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/era.10.190","article-title":"The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?","volume":"11","author":"Addeo","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdt359_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-012-1945-4","article-title":"Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases","author":"Addeo","year":"2012","journal-title":"Cancer Chemother Pharmacol. [Internet]."},{"issue":"1","key":"10.1093\/annonc\/mdt359_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0167-8140(94)90413-8","article-title":"Disruption of the blood\u2013brain barrier as the primary effect of CNS irradiation","volume":"31","author":"Rubin","year":"1994","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt359_bb0125","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/12\/2985\/16702011\/mdt359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:30:45Z","timestamp":1624519845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0923753419367225"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt359","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}